查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984089

功能基因體學市場：依產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Functional Genomics Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，功能基因體學市場價值將達到 10.8 億美元，到 2026 年將成長到 12.3 億美元，到 2032 年將達到 25.7 億美元，複合年成長率為 13.08%。

主要市場統計數據
基準年 2025 10.8億美元
預計年份：2026年 12.3億美元
預測年份 2032 25.7億美元
複合年成長率 (%) 13.08%

基於收集的資訊，對功能基因組學進行戰略概述，重點關注技術融合、解釋挑戰以及研究和臨床相關人員。

功能基因組學融合了分子生物學、計算分析和轉化研究，將基因組序列數據轉化為可操作的生物學見解。儀器、試劑化學和資訊科學的進步，使該領域從假設主導的單基因研究轉向高通量系統方法，從而闡明調控網路、突變功能和細胞異質性。這種發展使得研究人員和臨床醫生能夠以前所未有的解析度揭示基因表現動態、表觀遺傳修飾和基因型-表現型關係。

調查方法、整合解決方案和不斷變化的監管預期方面的創新正在重塑功能基因組學的應用路徑和經營模式。

功能基因組學領域正經歷著一場變革性的轉型，其驅動力來自調查方法、數據整合以及新興的轉化應用預期等方面的創新。在調查方法方面，長讀長定定序和單細胞技術的成熟拓展了可檢測突變和細胞狀態的範圍，而聚合酵素鏈鎖反應(PCR) 和標靶檢測技術的演進則持續提供經濟高效的檢驗途徑。伴隨這些技術進步，雲端原生分析工具和機器學習框架的蓬勃發展也使得可擴展的解讀和可重複的工作流程成為可能。

2025 年貿易措施的營運影響，以及相關人員為維持調查和服務交付的連續性而實施的策略供應鏈調整。

關稅的引入和貿易政策的調整可能會在全球生命科學供應鏈中造成重大摩擦，影響試劑分銷、儀器採購和軟體許可等各個環節。特別是，美國在2025年實施的措施影響了籌資策略和合約條款，促使製造商和經銷商重新評估其供應商網路、庫存緩衝和物流緊急時應對計畫。這些貿易政策的變化凸顯了供應鏈韌性的重要性，以及為維持科學研究和診斷工作流程的連續性而實現採購管道多元化的必要性。

詳細的細分分析揭示了產品、技術、應用和最終用戶的交集，從而決定了產品採用的優先順序和商業化策略。

市場區隔洞察清晰地揭示了價值創造的集中領域以及營運重點與最終用戶需求的契合點。產品類型細分檢驗表明，產品組合包括耗材和試劑、儀器以及軟體和服務，其中軟體和服務又可進一步細分為服務和軟體產品。這種區分凸顯了實體耗材與數位化工作流程之間的相互依存關係，也解釋了為何許多組織優先考慮整合採購和售後支援。從技術角度來看，產品組合涵蓋微陣列平台、次世代定序技術、PCR 和 qPCR 系統、PCR 晶片以及RNA干擾篩檢，其中次世代定序本身包含 Illumina、Oxford Nanopore Technologies、Pacific Biosciences 和 Thermo Fisher Ion Torrent 等代表性平台。了解這些技術家族有助於相關人員透過將檢測需求與平台優勢（例如靈敏度、讀取長度和通量）相匹配來最佳化檢測方案。

影響美洲、歐洲、中東和非洲以及亞太地區實施和夥伴關係模式的區域趨勢和戰略考量

區域趨勢對整個功能基因組學生態系統的技術應用、監管路徑和夥伴關係模式都具有至關重要的影響。在美洲，研究基礎設施、創業投資活動以及大型製藥企業和生物技術公司緊密的合作網路正在推動先進平台的早期應用，並促進設備供應商和臨床檢查室之間的垂直整合合作。該地區的法規結構和報銷環境鼓勵轉化研究計劃和公私合作聯盟，從而降低臨床檢驗的風險。

競爭格局洞察顯示，硬體、試劑和軟體的整合策略如何推動功能基因體學領域的差異化和長期客戶維繫。

功能基因組學領域的競爭動態由成熟的儀器供應商、專業的試劑創新者和能夠實現數據解讀和工作流程自動化的軟體供應商共同塑造。成熟的儀器供應商持續投資於平台改進和服務網路，重點關注可靠性、處理能力和法規遵從性；而試劑生產商則透過創新的化學技術、批間一致性和簡化的樣品製備試劑盒來脫穎而出。軟體和服務供應商在將原始資料轉化為可執行的洞見方面發揮著越來越重要的作用，他們提供整合流程、雲端分析和託管服務，從而縮短從實驗到決策的時間。

著眼於供應鏈韌性、互通性分析、服務模式和監管合規性，制定切實可行的策略挑戰，以確保競爭優勢。

產業領導企業應採取務實的投資組合層面策略，在短期業務永續營運和長期創新之間取得平衡。首先，企業必須優先考慮供應鏈多元化和合約柔軟性，以降低貿易政策波動和零件短缺的風險。這包括選擇替代供應商、建立區域採購方案以及在採購合約中加入緊急條款。其次，投資於可互通的軟體和標準化資料格式將減少整合摩擦，加速跨平台分析，並使客戶能夠更有效率地從原始資料得出經過檢驗的結論。

採用嚴謹的混合方法研究途徑，結合相關人員訪談、文獻整合和技術比較評估，確保獲得可重複和可操作的見解。

本執行報告的調查方法融合了多種定性和定量方法，以確保研究結果的嚴謹性和可重複性。主要研究包括與各類相關人員進行結構化訪談和討論，這些利害關係人包括學術研究人員、臨床實驗室管理人員、採購經理和產業研發負責人。這些對話有助於深入了解技術需求、應用限制和營運重點，從而為最終的解釋性結論奠定基礎。

一份統一的報告，明確了實現功能基因組學潛力所需的策略重點、營運促進因素和基本合作要求。

總而言之，在定序、PCR技術和整合分析技術進步的推動下，功能基因組學正從一門探索性學科轉變為發現和臨床工作流程中的一項重要組成部分。這項轉變要求相關人員協調設備、耗材和軟體方面的投資，以實現可重複、高品質資料的生成和解讀。供應鏈韌性、監管合作和人力資源能力是決定哪些機構能夠在研究和臨床應用情境中擴展功能基因體學的關鍵因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 功能基因體學市場：依產品類型分類

  • 耗材和試劑
  • 裝置
  • 軟體服務
    • 服務
    • 軟體

第9章 功能基因體學市場：依技術分類

  • 微陣列
  • 次世代定序
    • Illumina
    • 牛津奈米孔技術公司
    • 太平洋生物科學
    • Thermo Fisher ION Trent
  • PCR和qPCR
  • PCR晶片
  • RNA干擾篩檢

第10章 功能基因體學市場：依應用領域分類

  • 表觀遺傳學
  • 基因表現分析
  • 基因型鑒定
  • RNA干擾篩檢

第11章 功能基因體學市場：依最終用戶分類

  • 學術和研究機構
  • 醫院和診斷中心
  • 製藥和生物技術公司

第12章 功能基因體學市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 功能基因體學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 功能基因體學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國功能基因體學市場

第16章：中國功能基因體學市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • AstraZeneca plc
  • Bio-Rad Laboratories, Inc.
  • Biomatters Limited
  • Bionano Genomics, Inc.
  • C2i Genomics
  • Congenica Ltd.
  • Danaher Corporation
  • Eagle Genomics
  • Eppendorf SE
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • Fabric Genomics, Inc.
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Nest Health Tech Inc.
  • Novogene Co., Ltd.
  • Oxford Nanopore Technologies PLC
  • Pacific Biosciences of California, Inc.
  • Personalis, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Rapid Genomics by LGC Biosearch Technologies
  • Thermo Fisher Scientific Inc.
  • Vizgen, Inc.
Product Code: MRR-2E76C3E47FBB

The Functional Genomics Market was valued at USD 1.08 billion in 2025 and is projected to grow to USD 1.23 billion in 2026, with a CAGR of 13.08%, reaching USD 2.57 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.08 billion
Estimated Year [2026] USD 1.23 billion
Forecast Year [2032] USD 2.57 billion
CAGR (%) 13.08%

An informed strategic overview of functional genomics highlighting technological convergence, interpretive challenges, and operational priorities for research and clinical stakeholders

Functional genomics sits at the intersection of molecular biology, computational analytics, and translational research, translating genomic sequence data into actionable biological understanding. Advances in instrumentation, reagent chemistries, and informatics have moved the discipline from hypothesis-driven single-gene studies to high-throughput systems approaches that reveal regulatory networks, variant function, and cellular heterogeneity. This evolution has enabled researchers and clinicians to probe gene expression dynamics, epigenetic modifications, and genotype-phenotype relationships with unprecedented resolution.

Consequently, stakeholders across academic institutions, diagnostic centers, and industry are integrating functional genomics into workflows that inform target discovery, biomarker development, and therapeutic stratification. The convergence of next-generation sequencing refinements, novel PCR modalities, and scalable software platforms has reduced technical barriers while increasing the depth and granularity of biological insight. Transitioning from data generation to data interpretation remains a central challenge, necessitating investments in computational expertise, standardized protocols, and cross-disciplinary collaboration.

This executive summary synthesizes contemporary drivers, segmentation nuances, regional dynamics, and strategic imperatives shaping the field. It aims to equip leaders with a concise, evidence-based perspective that supports tactical planning, partnership formulation, and resource allocation in an environment where rapid technological iteration and regulatory shifts co-determine competitive positioning and scientific impact.

How methodological innovation, integrated solutions, and evolving regulatory expectations are reshaping adoption pathways and commercial models in functional genomics

The landscape of functional genomics is undergoing transformative shifts driven by methodological innovation, data integration, and new translational expectations. Methodologically, the maturation of long-read sequencing and single-cell approaches is extending the scope of detectable variants and cellular states, while polymerase chain reaction evolutions and targeted assays continue to provide cost-effective validation pathways. These technical advances are paralleled by a surge in cloud-native analytics and machine learning frameworks that enable scalable interpretation and reproducible workflows.

On the operational front, partnerships between instrument manufacturers, reagent suppliers, and software developers are fostering vertically integrated solutions that reduce time to insight and simplify adoption. At the same time, decentralized testing and point-of-care initiatives are prompting platform providers to optimize for portability, speed, and regulatory compliance. Regulatory expectations are shifting toward greater transparency around assay performance and data provenance, prompting vendors and end users to prioritize validated pipelines and robust quality controls.

Finally, commercial models are adjusting to emphasize recurring revenues from consumables and services alongside one-time instrument sales, thereby reshaping investment and customer engagement strategies. Collectively, these shifts are accelerating the translation of functional genomics from experimental discovery to routine clinical and industrial application, while also raising the bar for interoperability, data governance, and cross-sector collaboration.

Operational implications of 2025 trade measures and strategic supply chain adaptations that stakeholders implemented to sustain research continuity and service delivery

The introduction of tariffs and trade policy adjustments can create material friction across the global life sciences supply chain, affecting reagent flows, instrument procurement, and software licensing ecosystems. In particular, measures implemented in 2025 in the United States have influenced sourcing strategies and contractual terms, prompting manufacturers and distributors to reassess supplier networks, inventory buffers, and logistical contingency plans. These trade policy changes have underscored the importance of supply chain resilience and the need to diversify procurement pathways to maintain continuity for research and diagnostic workflows.

Organizations responded by accelerating regional supplier identification and by exploring manufacturing flexibility, including contract manufacturing and localized reagent production. Procurement teams increased emphasis on multi-sourcing clauses and on renegotiating lead times to mitigate exposure to tariff volatility. Additionally, the tariffs highlighted the strategic value of service offerings and digital delivery models that can be decoupled from physical trade constraints, such as cloud-based analytics subscriptions and remote instrument monitoring services.

From a strategic standpoint, the episode reinforced the imperative for integrated risk assessments that account for policy shifts, and for proactive engagement with logistics partners and customs advisors. Entities that invested in scenario planning and in establishing alternate supply corridors reported more stable operations, while those with single-source dependencies experienced longer recovery timelines. The broader lesson is that trade policy is a persistent variable in operational planning and requires continuous monitoring and adaptive contracting to preserve programmatic momentum.

Deep segmentation analysis revealing product, technology, application, and end-user intersections that determine adoption priorities and commercialization strategies

Insight into market segmentation clarifies where value creation is concentrated and where operational priorities align with end-user needs. When examining segmentation by product type, the landscape includes consumables and reagents, instruments, and software and services, with the latter further divided into services and software offerings; this delineation emphasizes the interdependence of physical consumables and digital workflows and signals why many organizations prioritize integrated purchasing and post-sale support. From a technology perspective, the portfolio spans microarray platforms, next-generation sequencing modalities, PCR and qPCR systems, PCR arrays, and RNA interference screening, with next-generation sequencing itself comprising major platform archetypes such as Illumina, Oxford Nanopore Technologies, Pacific Biosciences, and Thermo Fisher Ion Torrent; understanding these technology families helps stakeholders match assay requirements to platform strengths for sensitivity, read length, and throughput.

Application segmentation highlights core use cases including epigenetics, gene expression analysis, genotyping, and RNA interference screening, each of which imposes distinct requirements on sample preparation, detection sensitivity, and bioinformatics interpretation. Finally, end user segmentation identifies primary demand drivers across academic and research institutes, hospitals and diagnostic centers, and pharmaceutical and biotech companies, illuminating how purchasing rationales differ between discovery-oriented research and regulated clinical environments. By integrating these segmentation lenses, organizations can better prioritize product development, align commercial messaging to user workflows, and design service bundles that reduce adoption friction while improving scientific outcomes.

Comparative regional dynamics and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape adoption and partnership models

Regional dynamics exert a decisive influence on technology adoption, regulatory pathways, and partnership models across the functional genomics ecosystem. In the Americas, research infrastructure, venture capital activity, and a dense network of large pharmaceutical and biotech organizations drive early adoption of advanced platforms and foster vertically integrated collaborations between instrument vendors and clinical laboratories. Regulatory frameworks and reimbursement environments in this region incentivize translational projects and public-private consortia that de-risk clinical validation pathways.

Across Europe, Middle East & Africa, the landscape is heterogeneous, with pockets of leading academic centers and national initiatives promoting genomics medicine alongside markets where access and infrastructure vary considerably. Harmonization efforts and pan-regional partnerships are pivotal in scaling multi-center studies and in implementing standardized data governance protocols. Meanwhile, capacity building and public health genomics programs are expanding the relevance of decentralized and cost-effective solutions.

In the Asia-Pacific region, rapid investments in genomics infrastructure, a growing diagnostics market, and an expanding base of contract research organizations support accelerated uptake of both established and emerging technologies. Local manufacturing and supportive industrial policies have encouraged supply-chain localization and public-private collaborations, shaping acquisition strategies for instruments, reagents, and informatics platforms. Across all regions, strategic entrants are tailoring their value propositions to reflect local regulatory expectations, reimbursement realities, and ecosystem maturity.

Competitive landscape insights showing how integrated hardware, reagent, and software strategies drive differentiation and long-term customer retention in functional genomics

Competitive dynamics in functional genomics are shaped by a mixture of legacy instrument incumbents, specialized reagent innovators, and software providers enabling data interpretation and workflow automation. Established instrument vendors continue to invest in platform improvements and service networks that emphasize reliability, throughput, and regulatory support, while reagent manufacturers differentiate through novel chemistries, lot-to-lot consistency, and streamlined sample preparation kits. Software and services providers are increasingly essential in converting raw data into usable insights, offering integrated pipelines, cloud analytics, and managed services that reduce the time from experiment to decision.

Strategic activities include collaborations between instrument manufacturers and bioinformatics firms, acquisitions aimed at expanding end-to-end offerings, and partnerships with contract research organizations to embed platforms into large-scale studies. Companies that succeed tend to pair strong technical performance with robust customer support, transparent validation datasets, and flexible commercial models that accommodate both research and clinical buyers. Additionally, investment in education, technical training, and community engagement-such as user forums and application-focused workshops-strengthens market position by lowering adoption barriers and fostering user loyalty.

Going forward, competitive advantage will accrue to organizations that can seamlessly integrate hardware, chemistry, and software, while also demonstrating compliance with evolving regulatory expectations and delivering reproducible results across diverse sample types and study designs.

Actionable strategic imperatives emphasizing supply chain resilience, interoperable analytics, service models, and regulatory readiness to secure competitive advantage

Industry leaders should adopt a pragmatic, portfolio-level approach that balances near-term operational resilience with long-term innovation. First, organizations must prioritize supply chain diversification and contract flexibility to mitigate risks associated with trade policy shifts and component shortages. This includes qualifying alternative suppliers, establishing regional sourcing options, and embedding contingency terms in procurement contracts. Second, investment in interoperable software and standardized data formats will reduce integration friction and accelerate cross-platform analytics, enabling customers to move from raw data to validated conclusions more efficiently.

Third, companies should pivot to service-centric models where appropriate, bundling assays, validation services, and analytics support to create recurring revenue streams and deepen client relationships. Fourth, enhanced regulatory readiness-through preemptive validation studies, rigorous documentation, and proactive engagement with regulators-will shorten clinical adoption pathways and build trust among diagnostic customers. Fifth, leaders must commit to workforce development by supporting end-user training, certification programs, and knowledge transfer initiatives that lower technical barriers and scale adoption.

Finally, strategic partnerships that combine localized manufacturing, regional distribution expertise, and domain-specific bioinformatics capabilities will offer competitive advantages in markets with distinct regulatory and infrastructural profiles. Collectively, these actions will position organizations to convert technological advances into sustained scientific and commercial impact.

Rigorous mixed-method research approach combining stakeholder interviews, literature synthesis, and comparative technology assessment to ensure reproducible, actionable insights

The research methodology underpinning this executive synthesis integrates multiple qualitative and quantitative approaches to ensure rigorous, reproducible insights. Primary research included structured interviews and consultative discussions with a cross-section of stakeholders spanning academic investigators, clinical laboratory directors, procurement leads, and industry R&D heads. These interactions provided contextual understanding of technology needs, adoption inhibitors, and operational priorities that inform interpretive conclusions.

Secondary research comprised review of peer-reviewed literature, conference proceedings, regulatory guidance documents, and company technical disclosures to validate technological trends and to map product portfolios. Where appropriate, comparative technology assessments were conducted to articulate platform strengths and limitations across typical applications such as gene expression profiling, epigenetic analysis, and variant functionalization. Triangulation of primary insights with secondary sources ensured robustness and helped identify consensus themes and areas of friction.

Analytical methods emphasized thematic synthesis over raw extrapolation, with attention to reproducibility, data provenance, and methodological transparency. Limitations of the analysis are acknowledged and are addressed through recommended follow-up assessments and potential commissioning of bespoke studies tailored to specific organizational questions.

Concluding synthesis that distills strategic priorities, operational enablers, and collaborative imperatives required to realize the promise of functional genomics

In summary, functional genomics is transitioning from an exploratory discipline to an operationalized component of discovery and clinical workflows, catalyzed by advances in sequencing, PCR technologies, and integrative analytics. This transition requires stakeholders to align investments across instrumentation, consumables, and software to enable reproducible, high-quality data generation and interpretation. Supply chain resilience, regulatory engagement, and workforce capability are central enablers that will determine which organizations can scale functional genomics across research and clinical use cases.

Strategic focus should concentrate on delivering integrated solutions that reduce total cost of ownership and on cultivating partnerships that bridge academic, clinical, and commercial spheres. Moreover, firms that prioritize interoperability, transparent validation, and end-user training will lower adoption barriers and accelerate the translation of genomic insights into tangible outcomes. The field presents meaningful opportunities for those who can marry technical excellence with pragmatic commercialization and service delivery, while remaining responsive to policy developments and regional market nuances.

Ultimately, success will depend on the capacity to convert complex data into decision-ready evidence, to manage operational risk, and to sustain collaborative ecosystems that amplify scientific discovery and patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Functional Genomics Market, by Product Type

  • 8.1. Consumables & Reagents
  • 8.2. Instruments
  • 8.3. Software & Services
    • 8.3.1. Services
    • 8.3.2. Software

9. Functional Genomics Market, by Technology

  • 9.1. Microarray
  • 9.2. Next-Generation Sequencing
    • 9.2.1. Illumina
    • 9.2.2. Oxford Nanopore Technologies
    • 9.2.3. Pacific Biosciences
    • 9.2.4. Thermo Fisher Ion Torrent
  • 9.3. PCR & qPCR
  • 9.4. PCR Arrays
  • 9.5. RNA Interference Screening

10. Functional Genomics Market, by Application

  • 10.1. Epigenetics
  • 10.2. Gene Expression Analysis
  • 10.3. Genotyping
  • 10.4. RNA Interference Screening

11. Functional Genomics Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Hospitals & Diagnostic Centers
  • 11.3. Pharmaceutical & Biotech Companies

12. Functional Genomics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Functional Genomics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Functional Genomics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Functional Genomics Market

16. China Functional Genomics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 10x Genomics, Inc.
  • 17.6. Agilent Technologies, Inc.
  • 17.7. AstraZeneca plc
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. Biomatters Limited
  • 17.10. Bionano Genomics, Inc.
  • 17.11. C2i Genomics
  • 17.12. Congenica Ltd.
  • 17.13. Danaher Corporation
  • 17.14. Eagle Genomics
  • 17.15. Eppendorf SE
  • 17.16. Eurofins Scientific SE
  • 17.17. F. Hoffmann-La Roche AG
  • 17.18. Fabric Genomics, Inc.
  • 17.19. Merck & Co., Inc.
  • 17.20. Myriad Genetics, Inc.
  • 17.21. Nest Health Tech Inc.
  • 17.22. Novogene Co., Ltd.
  • 17.23. Oxford Nanopore Technologies PLC
  • 17.24. Pacific Biosciences of California, Inc.
  • 17.25. Personalis, Inc.
  • 17.26. QIAGEN N.V.
  • 17.27. Quest Diagnostics Incorporated
  • 17.28. Rapid Genomics by LGC Biosearch Technologies
  • 17.29. Thermo Fisher Scientific Inc.
  • 17.30. Vizgen, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FUNCTIONAL GENOMICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FUNCTIONAL GENOMICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA FUNCTIONAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY ILLUMINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY ILLUMINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY ILLUMINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY OXFORD NANOPORE TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY OXFORD NANOPORE TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY OXFORD NANOPORE TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PACIFIC BIOSCIENCES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PACIFIC BIOSCIENCES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PACIFIC BIOSCIENCES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY THERMO FISHER ION TORRENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY THERMO FISHER ION TORRENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY THERMO FISHER ION TORRENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PCR & QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PCR & QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PCR & QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PCR ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PCR ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PCR ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY RNA INTERFERENCE SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY RNA INTERFERENCE SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY RNA INTERFERENCE SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY EPIGENETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY EPIGENETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY EPIGENETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GENOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY RNA INTERFERENCE SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY RNA INTERFERENCE SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY RNA INTERFERENCE SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 139. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 141. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 162. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 167. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 169. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA FUNCTIONAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)